Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telix PharmaceuticalsASX:TLX +4.28%59 3-Year Book Growth Rate is 93.40% as of Jun. 2026, which is 1254% above its 10-year median of 6.90. GuruFocus rates ASX:TLX with a GF Score™ of 59/100 and a GF Value™ of A$36.68 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,123 Biotechnology companies, Telix Pharmaceuticals ranks better than 97.42% on this metric.
During the past 12 months, Telix Pharmaceuticals's average Book Value per Share Growth Rate was 5.50% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 93.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 109.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Telix Pharmaceuticals was 492.60% per year. The lowest was -67.70% per year. And the median was 6.90% per year.
Telix Pharmaceuticals (ASX:TLX) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Telix Pharmaceuticals 3-Year Book Growth Rate Related Terms
ASX:TLX vs VRTX, REGN, MRNA: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's 3-Year Book Growth Rate falls into.
Telix Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 93.40% mean?
Telix Pharmaceuticals (ASX:TLX) has a 3-Year Book Growth Rate of 93.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Telix Pharmaceuticals and its competitors. This is 1254% above median its historical median of 6.90. According to the industry distribution chart, Telix Pharmaceuticals ranks #29 out of 1123 companies in the Biotechnology industry, placing it in the top 2.6%.
Is Telix Pharmaceuticals' 3-Year Book Growth Rate too high?
Telix Pharmaceuticals' current 3-Year Book Growth Rate of 93.40% is 1254% above median its 10-year median of 6.90. Based on the distribution chart, Telix Pharmaceuticals ranks #29 out of 1123 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #29 out of 1123 companies for 3-Year Book Growth Rate. This places Telix Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current 3-Year Book Growth Rate is 93.40%, which is 1254% above median its own 10-year median of 6.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$36.68, compared to a current price of A$16.34 — trading 55.5% below its estimated fair value. The current 3-Year Book Growth Rate is 93.40%, which is 1254% above median its 10-year median of 6.90. Telix Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current 3-Year Book Growth Rate is 93.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of A$16.34 is trading 55.5% below its estimated GF Value™ of A$36.68.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ASX:TLX:
3-Year Book Growth Rate: 93.40% (1254% above median its 10-year median of 6.90)
GF Value™: A$36.68 vs. price of A$16.34 (55.5% below fair value)
No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
59GF Score
Get the complete analysis for ASX:TLX
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TLX has been successfully added to your 
